Success Metrics

Clinical Success Rate
93.3%

Based on 28 completed trials

Completion Rate
93%(28/30)
Active Trials
0(0%)
Results Posted
57%(16 trials)
Terminated
2(6%)

Phase Distribution

Ph phase_1
6
19%
Ph phase_3
5
16%
Ph phase_4
9
29%
Ph phase_2
4
13%
Ph not_applicable
2
6%

Phase Distribution

6

Early Stage

4

Mid Stage

14

Late Stage

Phase Distribution26 total trials
Phase 1Safety & dosage
6(23.1%)
Phase 2Efficacy & side effects
4(15.4%)
Phase 3Large-scale testing
5(19.2%)
Phase 4Post-market surveillance
9(34.6%)
N/ANon-phased studies
2(7.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.3%

28 of 30 finished

Non-Completion Rate

6.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

31

all time

Status Distribution
Completed(28)
Terminated(2)
Other(1)

Detailed Status

Completed28
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
31
Active
0
Success Rate
93.3%
Most Advanced
Phase 4

Trials by Phase

Phase 16 (23.1%)
Phase 24 (15.4%)
Phase 35 (19.2%)
Phase 49 (34.6%)
N/A2 (7.7%)

Trials by Status

completed2890%
terminated26%
unknown13%

Recent Activity

Clinical Trials (31)

Showing 20 of 31 trialsScroll for more
NCT03602508

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

Completed
NCT03946124Phase 4

Fall Prevention in Older Adults With OAB

Completed
NCT01661166Phase 4

A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy

Completed
NCT03572231

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

Completed
NCT02385500Phase 4

Fesoterodine on Urgency Episodes in Parkinson's Disease Population

Terminated
NCT02676154Phase 2

Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)

Completed
NCT02614482Phase 3

Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children.

Completed
NCT02327936Phase 3

Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children

Completed
NCT00943735

This Is An Open-Label Study To Evaluate Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder

Completed
NCT00911937Phase 4

A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency

Completed
NCT00691093

Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy

Completed
NCT00902187Phase 1

A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects

Completed
NCT00902681Phase 1

A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects

Completed
NCT02262936Phase 2

Comparison Between Desmopressin and Fesoterodine for Treatment of Night Time Voiding in Women Aged 65 and Older

Terminated
NCT01367886Not Applicable

Comparative Urine Proteomic Studies of Overactive Bladder in Humans

Completed
NCT01260311

Post Marketing Surveillance Of Fesoterodine In Filipino Patients With Over Active Bladder

Completed
NCT01054222Phase 4

Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder

Completed
NCT00928070Phase 4

A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder

Completed
NCT01595152Not Applicable

Solifenacin Succinate Versus Fesoterodine A Comparison Trial for Urgency Symptoms

Unknown
NCT01578304Phase 4

Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder

Completed

Drug Details

Intervention Type
DRUG
Total Trials
31